Welcome to our dedicated page for OBSV news (Ticker: OBSV), a resource for investors and traders seeking the latest updates and insights on OBSV stock.
ObsEva SA (OBSV) is a clinical-stage biopharmaceutical company pioneering novel therapies for women's reproductive health challenges. This comprehensive news hub provides essential updates on their therapeutic pipeline, clinical milestones, and strategic initiatives.
Investors and healthcare professionals will find timely information about linzagolix development progress, including regulatory submissions and trial data analysis. The resource also covers partnership announcements, financial updates, and scientific presentations relevant to uterine fibroid treatments and endometriosis care.
Key content areas include detailed reports on Phase 3 clinical trial outcomes, FDA/EMA regulatory communications, intellectual property developments, and market access strategies. All information is sourced directly from company filings and verified medical publications to ensure accuracy.
Bookmark this page for structured access to ObsEva's latest advancements in GnRH antagonist research and women's health solutions. Check regularly for updates on their mission to transform reproductive medicine through targeted therapeutic innovation.
ObsEva SA, a biopharmaceutical company focused on women's health, announced a transition for its common shares to trade under a new International Securities Identification Number (ISIN) starting April 25, 2023. This change follows the delisting of ObsEva's shares from the Nasdaq Capital Market effective March 23, 2023, and subsequent deregistration from the SEC.
The common shares will no longer be eligible for settlement through The Depository Trust Company (DTC) and will be managed by SIX SIS AG, the central securities depositary for the SIX Swiss Exchange. As of April 24, 2023, the old ISIN and CUSIP will be canceled, with trading commencing under the new ISIN CH1260041939.
Shareholders with custodians connected to SIX SIS will receive the new ISIN shares automatically, while others must arrange accordingly by the deadline.
ObsEva has released its U.S. Annual Report on Form 10-K for the fiscal year 2022, disclosing key financial results as of year-end 2022. The report can be accessed on its website. The company, focusing on women's reproductive health and pregnancy, is traded on the SIX Swiss Exchange under the ticker OBSN and on the OTC Pink Market as OBSVF. Additionally, ObsEva plans to publish its Swiss Annual Report to Shareholders, including IFRS results, in the week of April 24, 2023.
ObsEva SA announced its scheduled delisting from Nasdaq starting March 23, 2023, as it failed to maintain a minimum bid price of $1.00 per share for 30 consecutive days. The company received a notification on March 14, 2023, regarding this delisting, and it plans to file a Form 25-NSE with the SEC to deregister its securities under the U.S. Securities Exchange Act. Although the Nasdaq listing will cease, ObsEva intends to maintain its listing on the SIX Swiss Exchange under the ticker symbol “OBSN”. This transition is expected to lower its general and administrative costs.
ObsEva SA (NASDAQ: OBSV; SIX: OBSN) announced leadership changes on March 13, 2023. Ernest Loumaye has been appointed as Interim Chairman after Annette Clancy's resignation, serving until the 2023 Annual General Meeting. Fabien de Ladonchamps is set to become the new Chief Executive Officer on or about May 1, 2023, bringing 25 years of biotech experience. His prior roles at ObsEva helped raise over $110 million through equity financings. The company emphasizes a focus on women's health and reproductive therapies.
ObsEva SA (NASDAQ: OBSV) announced a strategic reorganization on February 24, 2023, focusing operations in Switzerland to conserve cash and prioritize the development of nolasiban, aimed at improving IVF success rates. The reorganization includes downsizing its US executive team and proposing a reduced Board of Directors. Notably, ObsEva expects to be delisted from Nasdaq due to non-compliance with listing rules and plans to deregister from the SEC, while maintaining its listing on the SIX Swiss Exchange. The changes are projected to result in annual savings of approximately $3.5 million. Furthermore, ObsEva extinguished $6.5 million in convertible debt.
ObsEva SA announced that a Geneva court has approved the withdrawal of its moratorium, confirming the company is no longer over-indebted. This decision follows the sale of rights to Ebopiprant to XOMA Corporation for $15 million, with potential milestone payments up to $98 million. ObsEva is now refocusing on nolasiban, aimed at improving in vitro fertilization success rates, retaining worldwide commercial rights except for China, where trials are set to begin with Yuyuan BioScience.
ObsEva SA provided an update on its compliance with Nasdaq's minimum stockholders’ equity requirement. Following a previous non-compliance notification, the company reported an increase in stockholders' equity to approximately $11.4 million as of November 30, 2022, due to the sale of rights to Ebopiprant to XOMA Corporation for $15 million, plus potential future milestones totaling up to $98 million. The company has submitted a plan to Nasdaq for continued compliance and has withdrawn its moratorium with Swiss courts due to reduced debt.
ObsEva SA announced a share capital increase, issuing 20,000,000 new shares at a price of 1/13 of a Swiss Franc each. Approved on December 8, 2022, this move aims to provide treasury shares for future fundraising and equity plans. The new shares will be fully subscribed by ObsEva USA Inc. and listed on the SIX Swiss Exchange around December 12, 2022. This capital increase comes amid ongoing challenges including potential risks related to debt obligations and compliance with Nasdaq listing rules.
